These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7526481)

  • 1. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
    Danhof M; de Boer A; Magnani HN; Stiekema JC
    Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
    Mikhailidis DP; Jagroop IA
    J Intern Med; 1998 Aug; 244(2):184. PubMed ID: 10095808
    [No Abstract]   [Full Text] [Related]  

  • 9. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
    Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
    Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
    van Barlingen HH; van Beek A; Erkelens DW; de Bruin TW
    J Intern Med; 1997 Aug; 242(2):125-9. PubMed ID: 9279289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen inhibits the heparin cofactor II-mediated antithrombin activity of dermatan sulfate.
    Zammit A; Dawes J
    Blood; 1995 Feb; 85(3):720-6. PubMed ID: 7833476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
    Magnani HN
    Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
    Castro-López V; Harris LF; O'Donnell JS; Killard AJ
    Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma.
    Zammit A; Pepper DS; Dawes J
    Thromb Haemost; 1993 Dec; 70(6):951-8. PubMed ID: 8165617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K; Neofotistos D; Ts'ao CH
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
    Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins.
    Williams EC; Huppert BJ; Asakura S
    J Lab Clin Med; 1992 Jul; 120(1):159-67. PubMed ID: 1377216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.